Dr Reddy’s Announces its Intent to Appeal Court Decision in Preliminary Injunction Hearing

Dr Reddy’s Laboratories Ltd. announced its intent to appeal the decision made by the US District Court for the District of New Jersey in a preliminary injunction hearing with respect to further sales and commercialization of Dr Reddy’s Buprenorphine and Naloxone Sublingual Film within the United States. The company disagrees with the court’s decision and will vigorously appeal it. Dr Reddy’s had announced the receipt of the approval, on June 15, 2018 by one of its wholly owned subsidiaries, from the US Food and Drug Administration (USFDA) for its Buprenorphine and Naloxone Sublingual Film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg, therapeutic equivalent generic version of Suboxone (buprenorphine and naloxone) sublingual film, in the United States market. – Medical Buyer Bureau